A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with

J Mehilli1, A Kastrati, J Dirschinger

  • 1Deutsches Herzzentrum, Munich, Germany.

Insights

This study found that both hand-mounted JoStent and premounted Multi-Link Duet coronary stents showed equivalent 1-year clinical and angiographic outcomes. These results indicate comparable safety and efficacy for both stent models in patients undergoing coronary interventions.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Coronary artery disease necessitates effective stent implantation.
  • Comparing different stent delivery systems is crucial for optimizing patient outcomes.
  • Hand-mounted and premounted stents offer distinct procedural advantages.

Purpose of the Study:

  • To compare the 1-year angiographic and clinical results of the hand-mounted JoStent and the premounted Multi-Link Duet coronary stent.
  • To assess the efficacy and safety of two distinct coronary stent models.
  • To determine if there are statistically significant differences in late lumen loss, restenosis, and target vessel revascularization between the two stent types.

Main Methods:

  • A multicenter randomized study involving 505 patients.
  • Random assignment to either the hand-mounted JoStent (n=252) or the premounted Multi-Link Duet stent (n=253).
  • Primary endpoint: late lumen loss at 1 year, with secondary endpoints including restenosis and target vessel revascularization.

Main Results:

  • Statistically equivalent late lumen loss: 1.12 mm (JoStent) vs. 1.17 mm (Multi-Link Duet) (P=0.02).
  • No significant difference in restenosis rates: 24.2% (JoStent) vs. 25.2% (Multi-Link Duet).
  • Similar target vessel revascularization rates: 13.9% (JoStent) vs. 15.4% (Multi-Link Duet).

Conclusions:

  • The hand-mounted JoStent and the premounted Multi-Link Duet stent achieve excellent procedural success rates.
  • Both stent models demonstrate equally favorable 1-year angiographic and clinical outcomes.
  • The choice between these stent models does not appear to significantly impact patient outcomes at one year.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...